SecBot SecBot

FATE

FATE THERAPEUTICS INC
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001434316 Biotech & Drug DiscoveryGenomics & Gene Editing
$1.14 −0.14 (−10.94%)
Nov 16 4:00 PM ET · prev $1.28
Market cap
$162.9M
Micro cap
Consensus
Buy
61% Buy or better · 18 analysts
Median target
$7.00
+514% · range $2.50–8.00
1 year
+17.5%
from $0.9700 · Nov 17
30 days
−38.7%
from $1.86
52-week range
$0.9700–3.11
−63% from high · low Nov 17
Avg volume 20D
1.61M
shares / day
Short interest
9.97M
≈8.2% of shares · −6.1%
Days to cover
8.3
at average volume
Insider net
−$319.6K
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read BEARISH 12 reports · 90 days
Balance 4 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 11/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $319.6K.

  • InstitutionsBEARISH

    Q3 2026: 13 added (0 new), 21 trimmed or exited.

  • AnalystsBULLISH

    11 of 18 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.276 → −$0.241 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −6.1% to 9.97M shares. 8.3 days to cover, ≈8.2% of shares.

  • TrendDOWNTREND

    46% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 61% rate it Buy or better
Strong Buy5Buy6Hold7Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +514%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Oct 27, 2026Wedbush
REITERATE
REITERATEOutperform
Aug 14, 2026Piper Sandler
REITERATE
REITERATEOverweight
Aug 14, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Aug 14, 2026Wedbush
REITERATE
REITERATEOutperform
Jun 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$319.6K
sold · 3 insiders
DateInsiderTypeValue
Nov 3, 2026
Adawi Kamal
Chief Financial Officer
Nov 3, 2026
SELL$13.5K
Aug 4, 2026
Valamehr Bahram
President and CEO
Aug 4, 2026
SELL$108.1K
Aug 4, 2026
TAHL CINDY
See Remarks
Aug 4, 2026
SELL$95.4K
Jun 12, 2026
Redmile Group, LLC
Director
Jun 12, 2026
AWARD87,900 sh
Jun 12, 2026
Lee Michael Stewart
Director
Jun 12, 2026
AWARD87,900 sh
Jun 12, 2026
Hamill Laura
Director
Jun 12, 2026
AWARD175,800 sh
Jun 12, 2026
ABERNETHY MATT
Director
Jun 12, 2026
AWARD87,900 sh
Jun 12, 2026
RASTETTER WILLIAM H
Director
Jun 12, 2026
AWARD87,900 sh

Earnings setup

Estimates
−$0.24
EPS estimate, this quarter
+12%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.24-$0.27–-$0.20+10.6%$154.3K
Next Q-$0.26-$0.33–-$0.23+5.2%$350.0K
Current FY-$0.97-$1.02–-$0.85+4.9%$3.5M
Next FY-$0.97-$1.30–-$0.69-0.1%$3.1M

Short side

FINRA· Oct 30, 2026
9,972,851
shares short
-6.1%
vs prior settlement
8.3
days to cover
≈8.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Fate Therapeutics' universal shelf registration (S-3, File No. 333-299862) became effective on November 12, 2026…
EFFECT · Impact 5/10
Nov 12, 2026 SEC
Fate Therapeutics filed a 424B5 prospectus supplement establishing a new $100M at-the-market (ATM) equity facility…
424B5 · Impact 4/10
Nov 9, 2026 SEC
Redmile Group filed Amendment No. 11 to its Schedule 13D solely to add Redmile Capital Offshore II Master Fund, Ltd…
SC 13D/A · Impact 2/10
Nov 5, 2026 Earnings
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single
Nov 3, 2026 Insider
Adawi Kamal sold 6,582 shares
Chief Financial Officer @ $2.05 ($13.5K)
Sep 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP · DOUBLED
2,374,346 shares ($5.6M)
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
1,664,316 shares ($3.9M)
Aug 14, 2026 Press
Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 5, 2026
Earnings
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free…
Oct 29, 2026
Earnings date
FATE Q3 2026 Earnings Scheduled · 2026-10-29
Oct 2, 2026
Press release
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to…
Oct 1, 2026
Earnings
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to…
Sep 25, 2026
Press release
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in…

SecBot reports

18 filings · 3 press releases · 1 bullish · 6 bearish · 11 neutral
All FATE filing & press-release reports (21)